Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled aztreonam in non-cystic fibrosis bronchiectasis with gram-negative endobronchial infection
NL-OMON35895Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchiectasis and Airways Infection comparing Cayston with Placebo (2 arms). Primary endpoint: Change in QOL-B Respiratory Symptoms score from baseline to end of placebo-controlled Course 1. Started Apr 2012; status: active, not recruiting.
02
Drugs
aztreonam
03
Conditions
bronchiectasisAirways Infection
Beyond the preview
Go deeper on NL-OMON35895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35895.